Bayesian estimation of cost-effectiveness ratios from clinical trials

Area of Science:

• Health Economics
• Biostatistics
• Clinical Trial Analysis

Background:

• Estimating the incremental cost-effectiveness ratio (ICER) presents significant statistical challenges.
• Standard ICER calculations can be problematic with treatments affecting both cost and effectiveness, or when effectiveness changes discontinuously.
• The ratio form of ICER complicates interpretation and analysis.

Purpose of the Study:

• To develop and present a novel Bayesian methodology for addressing difficulties in ICER estimation.
• To provide a more robust framework for analyzing cost-effectiveness data from clinical trials.
• To offer improved interval estimates and probability assessments for ICER.

Main Methods:

• Developed a Bayesian approach utilizing posterior probabilities for cost-effectiveness quadrants.
• Implemented simulation methods drawing from posterior distributions of cost and effectiveness parameters.
• Calculated separate interval estimates of ICER for specific quadrants of interest.

Main Results:

• The Bayesian methodology effectively addresses the inherent difficulties in standard ICER estimation.
• Provides posterior probabilities for different cost-effectiveness scenarios.
• Offers reliable interval estimates for ICER within relevant quadrants.

Conclusions:

• The proposed Bayesian methodology offers a superior alternative for estimating ICER in health economic evaluations.
• This approach enhances the interpretation and reliability of cost-effectiveness analyses.
• Facilitates better decision-making in healthcare resource allocation based on robust evidence.